Master dataINID | Criterion | Field | Content |
---|
| Type of IP right | SART | Patent |
| Status | ST | Pending/in force |
21 | DE file number | DAKZ | 60 2005 036 440.4 |
96 | EP file number | EAKZ | 05 85 2783.9 |
86 | WO file number | WAKZ | PCT/US2005/043668 |
97 | EP publication number | EPN | 1830838 |
87 | WO publication number | WPN | 2006060676 |
54 | Designation/title | TI | ZUBEREITUNGEN UND VERFAHREN ZUR BEHANDLUNG VON NEOPLASTISCHEN ERKRANKUNGEN |
51 | IPC main class | ICM (ICMV) | A61K 31/397 (2006.01) |
51 | IPC secondary class(es) | ICS (ICSV) | A61P 35/00 (2006.01) |
22 | DE application date | DAT | Dec 2, 2005 |
96 | EP application date | EAT | Dec 2, 2005 |
86 | WO application date | WAT | Dec 2, 2005 |
43 | Date of first publication | OT | Jun 8, 2006 |
| Date of publication of grant | PET | Oct 3, 2012 |
71/73 | Applicant/owner | INH | Dana-Farber Cancer Institute, Inc., Boston, Mass., US; Triphase Research and Development I Corp., Toronto, CA |
72 | Inventor | IN | CHAUHAN, Dharminder, Natick, Massachusetts 01760, US; PALLADINO,Michael A., OlivenhainCA 92024, US; ANDERSON, Kenneth, C., Wellesley, Massachusetts 02481, US |
74 | Representative | VTR | Grund Intellectual Property Group Patentanwälte und Solicitor PartG mbB, 80538 München, DE |
| Address for service | | Grund Intellectual Property Group Patentanwälte und Solicitor PartG mbB, 80538 München, DE |
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 633161 P Dec 3, 2004
|
| Patent division in charge | | 44 |
97 | EP language of publication | ELANG | EN - Englisch |
87 | WO language of publication | WLANG | EN - Englisch |
84 | Designated EP contracting states | EDS | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR |
| Published EP/WO documents | EPWOPN | Original document:
EP000001830838 Searchable text:
EP000001830838 Original document:
EP000001830838B1 Searchable text:
EP000001830838B1 Original document:
WO002006060676 Searchable text:
WO002006060676 |
43 | Date of first publication | EVT | Jun 8, 2006 |
| Date of the first transfer into DPMAregister | EREGT | May 26, 2011 |
| Date of the (most recent) update in DPMAregister | REGT | Nov 7, 2024 (Show all update days)(Hide all update days)- Nov 7, 2024
- Nov 9, 2023; Nov 10, 2022; Dec 11, 2021; Nov 30, 2021; Nov 11, 2021; Nov 24, 2020; Jan 18, 2020; Jan 11, 2019; Oct 25, 2018; Jan 18, 2018; Jan 11, 2018; Dec 9, 2016; Dec 5, 2015; Aug 25, 2015; May 6, 2015; Feb 13, 2015; Jul 16, 2014; Jan 8, 2014; Dec 19, 2013; Oct 31, 2013; Sep 24, 2013; May 2, 2013; Mar 12, 2013; Feb 16, 2013; Jan 30, 2013; Jan 29, 2013; Jan 10, 2013; Jan 8, 2013; Jan 5, 2013; Nov 29, 2012; Oct 11, 2012; Oct 5, 2012; Nov 17, 2011
- Historical data not available for this/these date(s)
- May 26, 2011
- Date of the first transfer into DPMAregister
|
View procedures New applicant/owner details (No.: 9)INID | Criterion | Field | Content
Close details
|
---|
| Type of procedure | VART | New applicant/owner details |
| Legal/procedural status | VST | New applicant/owner details |
| Date of legal/procedural status | VSTT | Mar 11, 2013 |
| Issue number | HN | 18 |
| Year | PJ | 2013 |
| Publication date | VT | May 2, 2013 |
| Type of publication | PART | Bibliographic data |
| Part | HT | Part 2 |
71/73 | Applicant/owner | INH | Dana-Farber Cancer Institute, Inc., Boston, Mass., US; Triphase Research and Development I Corp., Toronto, CA |
71/73 | Previous applicant/owner | INHF | Dana-Farber Cancer Institute, Inc., Boston, Mass., US, Nereus Pharmaceuticals, Inc., San Diego, Calif., US |